185 related articles for article (PubMed ID: 28391897)
1. A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin/kexin 9 inhibition.
Fahy EF; McCarthy E; Steinhagen-Thiessen E; Vaughan CJ
J Clin Lipidol; 2017; 11(1):287-288. PubMed ID: 28391897
[TBL] [Abstract][Full Text] [Related]
2. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
3. A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition.
Rodríguez-Jiménez C; Gómez-Coronado D; Frías Vargas M; Cerrato F; Lahoz C; Saban-Ruiz J; González-Nieto D; Lasunción MA; Mostaza JM; Rodríguez-Nóvoa S
Atherosclerosis; 2019 May; 284():223-229. PubMed ID: 30777337
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.
Tsakiridou ED; Liberopoulos E; Giotaki Z; Tigas S
J Clin Lipidol; 2018; 12(3):826-829. PubMed ID: 29650402
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH).
Muntoni S; Pisciotta L; Muntoni S; Bertolini S
J Clin Lipidol; 2015; 9(1):103-6. PubMed ID: 25670367
[TBL] [Abstract][Full Text] [Related]
6. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
7. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
8. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
[TBL] [Abstract][Full Text] [Related]
10. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
11. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
[TBL] [Abstract][Full Text] [Related]
12. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
[TBL] [Abstract][Full Text] [Related]
13. Autosomal recessive hypercholesterolemia in Spain.
Sánchez-Hernández RM; Prieto-Matos P; Civeira F; Lafuente EE; Vargas MF; Real JT; Goicoechea FG; Fuentes FJ; Pocovi M; Boronat M; Wägner AM; Masana L
Atherosclerosis; 2018 Feb; 269():1-5. PubMed ID: 29245109
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
[TBL] [Abstract][Full Text] [Related]
16. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
[TBL] [Abstract][Full Text] [Related]
17. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
Saußele T
Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
[No Abstract] [Full Text] [Related]
19. [Are there different responses to different PCSK9 inhibitors?].
Asenjo Mota Á; Caamaño Selma O; Sánchez-Aquino González R
Hipertens Riesgo Vasc; 2020; 37(1):42-44. PubMed ID: 31064717
[TBL] [Abstract][Full Text] [Related]
20. The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.
Smith L; Mosley J; Yates J; Caswell L
J Pharm Pharm Sci; 2016; 19(1):137-46. PubMed ID: 27096698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
